SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

Summary

The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).

Timeline

Start

2025-07-26

Primary completion

2027-06-26

Completion

2029-06-26

Drugs

Indications